Aegros is pleased to announce the appointment of Ernest & Young (EY) as our new Auditors.
The Board of Aegros has resolved to appoint EY as the Company’s Auditors replacing Hall Chadwick, effective for the 2022-23 Audit. The Board has taken this action as part of the Company’s preparation for an expected IPO in the 2024 calendar year. The Board would like to thank Hall Chadwick for its work completing the 2018-19 to 2021-22 year audits. The decision to change Auditors does not reflect on this work, but rather a desire to lift the level of expertise in the BioPharma space, which EY brings. This change is one of the many required to prepare Aegros for a potential IPO in the 2024 calendar year.
The Board would like to reiterate that an IPO is not a goal of the Company, but rather a result of achieving the following Company Goals:
Completion of the Covid-19 hyperimmune Clinical trial;
- Completion of the Covid-19 hyperimmune Clinical trial;
- Completion of the renovations to expand the Covid-19 Hyperimmune manufacturing capacity to 100,000L pa. This includes obtaining TGA GMP registration for this expanded facility; and
- First sales of Aegros Covid-19 Hyperimmune. This includes obtaining TGA Australian Register Therapeutic Goods (ARTG) licensure.
While a number of these goals are outside of the Company’s control, it is never the less, working towards achievement of these goals by 30 June 2024.
On behalf of the Board